CRMP5 Optic Neuritis: Diagnostic Work-up and Treatment
For suspected CRMP5-associated optic neuritis, immediately obtain serum CRMP5 (anti-CV2) antibody testing and initiate aggressive cancer screening for small-cell lung cancer, as this is a paraneoplastic syndrome requiring urgent tumor identification and high-dose immunosuppression to prevent irreversible vision loss.
Diagnostic Work-up
Clinical Recognition
CRMP5 optic neuritis presents with a distinctive triad that should trigger immediate serologic testing 1:
- Optic disc edema (present in all documented cases at symptom onset)
- Retinitis and/or vitritis (82% have concurrent intraocular inflammation)
- Absence of optic nerve enhancement on MRI (key distinguishing feature from typical demyelinating optic neuritis)
The median presenting visual acuity is 20/50, but can range from 20/20 to counting fingers 1. Bilateral involvement is common, and symptoms often precede cancer diagnosis in 72% of cases 1.
Essential Laboratory Testing
- Serum CRMP5 IgG antibody (titer >1:240 is diagnostic) 1
- Test both serum and CSF when available
- Note: Antibodies may be undetectable initially and appear after symptom onset 2
Imaging Protocol
MRI orbits with fat-saturated sequences 3:
- Look for optic disc edema on fundoscopy
- Confirm absence of optic nerve enhancement (distinguishes from MS, MOGAD, NMO) 1
- Brain and spine MRI to exclude alternative diagnoses 4
Critical pitfall: The lack of optic nerve enhancement differentiates CRMP5 optic neuritis from typical demyelinating causes. Do not dismiss the diagnosis based on negative MRI enhancement 1.
Cancer Screening
Immediate and comprehensive oncologic work-up 1, 5:
- Small-cell lung cancer is found in 83% of CRMP5-positive patients with neuro-ophthalmic manifestations
- CT chest/abdomen/pelvis
- PET-CT for occult malignancy
- Consider thymoma screening (less common association)
- 62% overall cancer detection rate in CRMP5 optic neuritis patients 1
Treatment Approach
Acute Immunosuppression
High-dose corticosteroids are first-line 6:
- Initiate immediately upon clinical suspicion
- Can prevent loss of high-contrast vision and improve contrast sensitivity 6
- 50% of patients show visual improvement with immunosuppressive therapy 1
Escalation therapy when steroids insufficient 5:
- Plasmapheresis (consider early in severe cases) 6
- Intravenous immunoglobulins (IVIG)
- Rituximab (anti-CD20 monoclonal antibody for B-cell depletion) 5, 7
- Methotrexate 5
Tumor-Directed Therapy
Cancer treatment is essential for neurologic stabilization 8:
- Surgical resection when feasible
- Chemotherapy/radiation as indicated
- Symptoms may improve after tumor removal 8
Special Considerations
Immune checkpoint inhibitor caution 2:
- ICIs can trigger or dramatically worsen CRMP5-PNS
- 83% of patients with preexisting CRMP5-PNS worsened on ICIs (median mRS increase of 1.5 points)
- Post-ICI CRMP5-PNS may be more severe than ICI-naïve cases
- Exercise extreme caution before initiating ICIs in patients with known CRMP5 antibodies
Prognosis considerations 6, 1:
- Visual recovery is generally poorer than typical MS-associated optic neuritis
- Optic nerve atrophy is more severe than idiopathic optic neuritis
- Final median visual acuity 20/40 (range 20/20 to hand movements) 1
- Despite treatment, progressive visual loss can occur even with antibody negativization 5
Key Clinical Pearls
The combination of optic disc edema + retinitis/vitritis + absence of optic nerve enhancement is pathognomonic for CRMP5 optic neuritis and should prompt immediate CRMP5 antibody testing and cancer screening 1. Early recognition is critical because neuro-ophthalmic symptoms precede cancer diagnosis in most cases, providing an opportunity for earlier oncologic intervention 1, 8.